Return to Provider News

Medical Policy Update: Bioengineered Tissue Products for Wound Treatment

Audience: Surgeons

Excellus BlueCross BlueShield works to ensure that the development of corporate medical policies occurs through an open, collaborative process. We encourage participating providers to become actively involved in medical policy development. Each month, draft policies are available on our website for review and comment here. Providers now have the capability of attaching supporting documentation related to their comments.

The following updated medical policy has been reviewed and was approved on June 16, 2022, by the Corporate Medical Policy Committee, which includes practitioners from all Health Plan regions. 

Corporate Medical Policy 7.01.35 – Bioengineered Tissue Products for Wound Treatment and Surgical Interventions has been updated to be consistent with Food and Drug Administration (FDA) recommendations regarding the patient-provider informed decision making and prompt reporting of adverse effects associated with the use of acellular dermal matrix products in implant-based breast reconstruction.  This updated policy will be effective October 15, 2022. The policy applies to all lines of business, and to the services of all practitioners and facilities.

The Bioengineered Tissue Products for Wound Treatment and Surgical Interventions policy provides updates to the criteria for the following indications:

Breast Reconstruction

The rationale section of the medical policy provides information related to the Health Plan’s change in coverage criteria based on the FDA’s issued statement in 2021.

These services are subject to audit and policy updates at the Health Plan’s discretion. Access the individual policies here.

If you have any questions regarding this policy, please contact your Provider Relations representative.

Thank you for the quality of care and service that you provide to our members.

Related News
Streamlined Preauthorization for Medical Specialty Drugs for Commercial Fully Insured Members Effective January 1, 2023

Medicare Advantage Prior Authorization for Select Oncology Medications

Resumption of Utilization Review Requirements Suspended Under NYS Executive Order #4

Medical Policy Update: Minimally Invasive Treatments Prostatic Hyperplasia

Training Opportunity: eviCore Cardiology Preauthorization Tool



Utilization Management

IE Browser Modal